Smad4 plays a key role in TGF-β (transforming growth factor β)/Smad-mediated transcriptional responses. We show that Smad4 is sumoylated both in vivo and in vitro. Recent studies showed that sumoylation of Smad4 regulated its stability, but the effect of sumoylation on the intrinsic transcriptional activity of Smad4 was not defined. We show that overexpression of SUMO (small ubiquitin-related modifier)-1 and Ubc9 can inhibit a TGF-β-responsive reporter gene, whereas co-transfection with SUMO-1 protease-1 (SuPr-1) can increase the TGF-β response. We show further that mutation of the Smad4 sumoylation sites or co-transfection with SuPr-1 greatly increases Smad4 transcriptional activity. Moreover, direct fusion of SUMO-1 to the sumoylation mutant Smad4 potently inhibits its transcriptional activity. Thus, as it is being rapidly discovered that sumoylation inhibits the activities of many transcription factors, sumoylation also represses Smad4 transcriptional activity. The net effect of sumoylation of Smad4 can therefore be either stimulatory or inhibitory, depending on the target promoter that is analysed.
INTRODUCTION
The TGF-β (transforming growth factor β) family regulates various biological responses through transcriptional regulation of diverse genes [1] [2] [3] . The major members of the TGF-β family include TGF-βs, activins and BMPs (bone morphogenetic proteins). Smad proteins can transduce the TGF-β family signal from the cell surface to the nucleus [1] [2] [3] . Smad2 and Smad3 are phosphorylated by the TGF-β receptor kinase, and Smad1 is phosphorylated by the BMP receptor kinase [1] [2] [3] . These receptor phosphorylated Smads form heteromeric complexes with the common partner Smad4, which accumulate in the nucleus to regulate transcription [1] [2] [3] . In mammalian cells, Smad4 is the only member of the Smad family that can participate in TGF-β, activin and BMP transcriptional responses, which underscores its central role in TGF-β-family-mediated gene regulation [1] [2] [3] .
Three SUMO (small ubiquitin-related modifier) proteins, SUMO-1, SUMO-2 and SUMO-3, are present in higher eukaryotes [4] . SUMO-2 and SUMO-3 are 97 % similar to each other, but have only 50 % identity with the SUMO-1 protein that is the most studied [4] . Similar to ubiquitination, sumoylation is also carried out by three enzymes [4] . The E1 activating enzyme consists of an SAE1 (Aos1)-SAE2 (Uba2) heterodimer [4] . In mammalian cells, the E2 conjugating enzyme is Ubc9 [4] . Multiple proteins, including the PIAS [protein inhibitor of activated STAT (signal transducer and activator of transcription)] family members, the nucleoporin RanBP2 and the polycomb protein Pc2 have been shown to possess SUMO E3 ligase activities ( [5] [6] [7] and reviewed in [8] ). Sumoylation is a reversible process, and several SUMO proteases have been identified in mammalian cells [4, 8] .
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For example, SUMO-1 protease-1 (SuPr-1) has been shown to cleave SUMO-1 from PML (promyelocytic leukaemia protein) [9] and transcription factor Sp3 [10] . Whereas SUMO conjugation has diverse cellular functions, such as regulating protein stability and subcellular localization [4, 8] , SUMO modification often represses transcriptional activity of a number of transcription factors, such as Sp3, c-Jun, c-Myb, AP2, nuclear receptors and Elk-1, and the general co-activator p300 ( [10] [11] [12] [13] and reviewed in [14] ). For example, removal of SUMO-1 from Sp3 or p300 by co-transfection of SuPr-1 or co-transfection with SUMO-specific protease 3, or by mutation of the sumoylation sites, enables Sp3 and p300 to become much more potent activators [10, 13] . Moreover, fusion of SUMO-1 to sumoylation mutant Sp3 potently inhibits its transcriptional activity [10] . In addition to transcription factors, sumoylation of histone H4 causes repression through recruitment of HDAC (histone deacetylase) and HP1 (heterochromatin protein 1) [15] .
In an effort to understand Smad-mediated transcriptional control, we performed a yeast three-hybrid screen using both Smad3 and Smad4 as baits, and identified Ubc9 as a Smad-interacting protein. We show that in yeast, Ubc9, as well as SUMO-1, specifically interact with Smad4, but not with receptor-regulated Smads, such as Smad1, Smad2 and Smad3. We show further that Smad4 is sumoylated in mammalian cells and in vitro. Moreover, we find that sumoylation of Smad4 inhibits its transcriptional activity. Recent studies have shown that sumoylation of Smad4 regulates its stability [16] [17] [18] . Thus sumoylation of Smad4 has different roles, which may result in distinct transcriptional effects depending on which promoter is analysed.
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EXPERIMENTAL Yeast three-hybrid screen and two-hybrid assay
The yeast three-hybrid screen was performed as previously described [19] . Six cDNA clones of Ubc9 were identified from screening 4 × 10 6 transformants of a human foetal brain cDNA library, and two Ubc9 clones were identified from screening 2 × 10 6 transformants of a human liver library. To examine the interactions of Ubc9 and SUMO-1 with various Smads and derivatives in yeast, full-length Smads, Smad4 deletion mutants or Smad4 [K159R (Lys 159 → Arg)] fused to the LexA DNA-binding domain in the pEG202 vector were co-transformed into the EGY48 strain with Ubc9 or SUMO-1 cloned in the pJG4-5 vector and then analysed for β-galactosidase activity as previously described [19] .
In vitro sumoylation
GST (glutathione S-transferase)-SUMO-1 (1-97) [20] and GSTUbc9 [21] were expressed in and purified from Escherichia coli. The GST portion was removed by thrombin cleavage. The E1 heterodimeric enzyme SAE1 (Aos1)-SAE2 (Uba2) was partially purified from NIH 3T3 cells as previously described [22] . 35 S-labelled, Myc-tagged wild-type and mutant Smad4 were synthesized by in vitro translation using the SP6 TNT ® coupled transcription/translation system (Promega), and the in vitro sumoylation reactions were then performed as previously described [22] . The bound proteins were analysed by SDS/PAGE and visualized by autoradiography.
Detection of in vivo sumoylation
COS cells were co-transfected with Myc-tagged wild-type or mutant Smad4, together with a FLAG-tagged SUMO-1 plasmid [5] by LIPOFECTAMINE TM plus reagent. At 45 h after transfection, cells were harvested and lysed as previously described [23] . The lysis buffer was a 3:1 mixture of RIPA buffer (25 mM Tris/ HCl, pH 8.2, 50 mM NaCl, 0.5 % sodium deoxycholate, 0.5 % Nonidet P40, 0.1 % SDS and 0.1 % azide) and SDS sample buffer (5 % SDS, 0.15 M Tris/HCl, pH 6.8, and 30 % glycerol), plus 10 mM NEM (N-ethylmaleimide) and protease inhibitors. Cells were then sonicated briefly, boiled for 10 min, followed by centrifugation at 14 000 g for 20 min. The supernatant was quantified for protein concentration using a DC protein assay kit (BioRad). The same amount of total protein was diluted 10 times into PBS/0.5 % Nonidet P40, and immunoprecipitated with antiMyc antibody followed by immunoblot with anti-FLAG antibody. To detect SUMO modification of endogenous Smad4, COS cell lysates were immunoprecipitated by a specific anti-Smad4 antibody, followed by immunoblot with a specific anti-SUMO-1 antibody.
Immunoprecipitation and immunoblot
For analysis of GAL4 fusion protein expression levels, COS cells transfected by DEAE-dextran for reporter gene assay were used in immunoblot analysis. SW480.7 cells were transfected by LIPOFECTAMINE TM plus reagent for immunoblot analysis. Other procedures for immunoprecipitation and immunoblot were performed as previously described [24] , using antibodies against Myc (Sigma), FLAG (Sigma), Smad4 (Santa Cruz), SUMO-1 (Zymed), Renilla luciferase (Chemicon), actin (Santa Cruz) or the GAL4 DNA-binding domain (Upstate).
Luciferase reporter gene assay
Mv1Lu/L17, HaCaT, SW480.7 and COS cells in 60-mm-diameter dishes were transfected by DEAE-dextran and treated with or without 500 pM TGF-β for 18-24 h as previously described [25] . Luciferase activities were normalized with co-transfected Renilla luciferase control driven by pRL-TK (Promega). Results represent at least three independent transfections.
RESULTS
SUMO-1 and Ubc9 bind to Smad4, but not to receptor-regulated Smads in yeast
To identify Smad-interacting proteins, we performed a yeast three-hybrid screen using both Smad4 and Smad3 as bait and identified Ubc9. Subsequent analysis indicates that in the yeast two-hybrid assay, Ubc9 and SUMO-1 interact only with Smad4, but not with receptor-regulated Smads, such as Smad1, Smad2 and Smad3 ( Figure 1A ). Further studies in yeast indicate that SUMO-1 and Ubc9 interactions with Smad4 occur outside the Smad4 Cterminal domain ( Figure 1A ). Inspection of the Smad4 sequence reveals that the lysine residue at amino acid 159 (VK 159 DE) in the linker region is the only lysine residue in Smad4 that fits the consensus sumoylation site KXE (where represents a hydrophobic amino acid). Mutation of this lysine residue to arginine in Smad4 reduced its binding to both SUMO-1 and Ubc9 significantly ( Figure 1A ), suggesting that this lysine residue may be a major sumoylation site.
Smad4 is sumoylated in vitro
We also determined whether Smad4 can be sumoylated in an in vitro sumoylation assay.
35 S-labelled, Myc-tagged Smad4 was synthesized by in vitro translation. Addition of SUMO-1, E1 enzyme and Ubc9 led to the sumoylation of Myc-Smad4 (Figure 1B) . Two bands of sumoylated Smad4 were detected: a major band migrating at approx. 125 kDa, and a minor band migrating at approx. 145 kDa. Myc-Smad4 migrated at approx. 90 kDa. Attachment of one SUMO molecule can increase the molecular mass of a target protein on SDS gel by 12-20 kDa. The two in vitro sumoylated Smad4 bands may represent the addition of two and three SUMO-1 molecules respectively. Several potential sumoylation site mutants were also analysed in the assay. The K159R mutation decreased the 125 kDa band significantly and abolished the upper 145 kDa band. In contrast, mutation of Lys Figure 1B) .
Because the rest of the lysine residues in Smad4 do not share significant similarity with the consensus sumoylation site, we looked into other known examples of sumoylation at a nonconsensus site. Lys 65 (AK 65 CP) in PML is a major sumoylation site [26] . Since Lys 340 (FK 340 VP) and the Lys 113 (VK 113 YC) of Smad4 share certain similarities with the AK 65 CP sequence of PML, we generated the K340R and K113R mutants. The K340R mutant had little effect on Smad4 sumoylation (results not shown). Interestingly, the K113R mutant inhibited sumoylation, albeit not as potently as the K159R mutation ( Figure 1B) . Mutation of both K159 and K113 eliminated Smad4 sumoylation ( Figure 1B) , suggesting strongly that these two sites are the major sumoylation sites in vitro.
Smad4 is sumoylated in mammalian cells
We then analysed whether or not transfected Smad4 can be sumoylated. Myc-epitope-tagged Smad4 was co-transfected with FLAG-tagged or double FLAG-tagged SUMO-1 into COS cells. Cell lysates were immunoblotted with anti-Myc antibody. As shown in Figure 1(C) (upper panel) , co-transfection with FLAG-SUMO-1 led to the formation of a slow-migrating band, and co-transfection with double FLAG-SUMO-1 led to the formation of an even slower-migrating band, indicating that the slowmigrating bands are sumoylated products of Myc-Smad4. This is confirmed further by immunoprecipitation of the lysates with antiMyc antibody, followed by immunoblot with anti-FLAG antibody ( Figure 1C, lower panel) . The K159R mutation, and, to a lesser extent, the K113 mutation, decreased Smad4 sumoylation. Mutation of both Lys 113 and Lys 159 essentially eliminated the sumoylation. Thus Lys 159 , and, to a lesser extent, Lys 113 , are also the major sumoylation sites in vivo, in agreement with previous reports [16, 17] .
We have also analysed whether SUMO-2 and SUMO-3, which are similar to each other, but are more distinct from SUMO-1, can also sumoylate Smad4. As shown in Figure 1(D) , Smad4 can also be sumoylated by SUMO-2 and SUMO-3. Moreover, mutation of both Lys 113 and Lys 159 also abolished Smad4 sumoylation by SUMO-2 ( Figure 1D ). Thus Lys 159 and Lys 113 are also important for sumoylation by SUMO-2, and presumably by SUMO-3 as well.
To determine whether or not endogenous Smad4 is sumoylated in mammalian cells, COS cell lysates were immunoprecipitated with a monoclonal anti-Smad4 antibody, followed by immunoblot with a specific anti-SUMO-1 antibody. As shown in Figure 1(E) , a single band migrating at approx. 93 kDa was detected. Endogenous Smad4 migrates at 68 kDa. The size of the detected band suggests that endogenous Smad4 is sumoylated by the addition of two SUMO molecules.
Sumoylation can inhibit a TGF-β/Smad-mediated transcriptional response
We next analysed the effects of sumoylation on TGF-β/Smaddependent transcriptional responses. As shown in Figure 2(A) , transfection of SUMO-1 and Ubc9, either individually or together, inhibited the TGF-β induction of 3TP-Lux, a well-characterized TGF-β-responsive reporter gene. PIASy also inhibited the 3TP-Lux reporter gene (Figure 2A ). Co-transfection of SUMO-1, Ubc9 and PIASy inhibited the TGF-β response further (Figure 2A) . Whereas SUMO-1/Ubc9 significantly inhibited the 3TP-Lux reporter gene, the MMP2 (matrix metalloproteinase 2) and the p15 reporter genes (results not shown), they have modest effects on several other TGF-β-responsive reporter genes, suggesting the involvement of promoter specificity. In the reverse experiment, cotransfection of SuPr-1 increased the TGF-β response of 3TP-Lux, whereas it had little effect on the control pGL3-Luc ( Figure 2B ). Taken together, these observations suggest that sumoylation of Smad4 may be related to the inhibition of the TGF-β responses.
Since the global overexpression of SUMO/Ubc9 or SuPr-1 can affect many targets and therefore cause indirect effects, we performed more definitive assays below to determine whether or not sumoylation of Smad4 indeed affects its transcriptional activity.
Mutation of Smad4 sumoylation sites increases its transcriptional activity significantly
We compared the ability of the wild-type Smad4 Figure 3 (A). Thus these results suggest that sumoylation of Smad4 can inhibit its transcriptional activity.
To verify whether or not the increased activity of the Smad4 sumoylation mutants occurred at the transcriptional level, we used the GAL4 fusion assay, which measures the transcriptional activity directly. The GAL4 fusion assay was used previously to compare the transcriptional activity of the wild-type with that of the sumoylation mutant Sp3 [10] , Elk-1 [12] and p300 [13] , and to study histone H4 sumoylation [15] . As shown in Figure 3 (B), GAL4-Smad4 (K159R) has a significantly higher activity than GAL4-Smad4, and GAL4-Smad4 (K113R/K159R) has the highest activity. The same results were obtained in various cell types, including Mv1Lu/L17, HaCaT and COS cells, and these GAL4 fusion proteins were expressed at very similar levels ( Figure 3B ). Moreover, co-transfection with SuPr-1 greatly increased the transcriptional activity of the wild-type GAL4-Smad4, GAL4-Smad4 (K113R) and GAL4-Smad4 (K159R), but had little effect on the transcriptional activity of the GAL4-Smad4 (K113R/K159R) double mutant ( Figure 3C ). Expression of SuPr-1 modestly reduced the GAL4-Smad4 fusion protein levels ( Figure 3C ), probably due to competition for expression. Although overexpression of SuPr-1 may have other effects, the observation that the K113R/K159R double mutant activity is not increased further by SuPr-1 suggests that the activation effect on the wild-type Smad4, K113R and K159R probably occurs through the proteolytic removal of the SUMO. Thus these GAL4 fusion studies indicate that sumoylation of Smad4 inhibits its transcriptional activity.
Fusion of SUMO-1 to Smad4 sumoylation mutants potently inhibit their transcriptional activities
To provide further evidence that sumoylation inhibits Smad4 transcriptional activity, we used the SUMO-1 fusion assay to covalently attach SUMO-1 to Smad4 by gene fusion. This generated a form of Smad4 that was constitutively sumoylated without the complications of indirect effects associated with overexpression of the SUMO-1-conjugating enzymes. The SUMO fusion method was used to demonstrate that sumoylation inhibits Sp3 transcriptional activity [10] . Similarly, previous studies have created LexA-ubiquitin-VP16 fusion to covalently attach ubiquitin to the transcriptional activation domain of VP16 [27] . This strategy of ubiquitin fusion to VP16 was used to demonstrate that activator ubiquitination is essential for transcriptional activation [27] . As shown in Figure 4 , the transcriptional activity of GAL4-SUMO-1-Smad4 (K159R) and especially GAL4-SUMO-1-Smad4 (K113R/K159R) were reduced dramatically compared with their counterparts without SUMO-1. Very similar results were obtained in various cell lines that we examined, including HaCaT, Mv1Lu/L17 and COS cells (Figure 4 ; and results not shown). Fusion of SUMO-1 decreased their protein expression levels only modestly (Figure 4, lower panel) . Thus sumoylation of Smad4 represses its transcriptional activity. 
DISCUSSION
Previous studies have shown that sumoylation of Smad4 regulates its stability, which can lead to the increased expression of certain TGF-β-family-responsive genes [16] [17] [18] . However, the effect of sumoylation on the intrinsic transcriptional activity of Smad4 was not determined. The Smad4 sumoylation mutant K113R/K159R displays reduced polyubiquitination [18] , leading to increased stability as analysed in the pulse-chase experiments ( [17, 18] ; J. Long and F. Liu, unpublished work). Based on these observations, it was concluded that sumoylation of Smad4 increases its stability. However, since mutation of the sumoylation sites leads to increased stability of Smad4, it is possible that SUMO modification is actually associated with decreased stability. Future studies are required to resolve this complex issue. In any case, the increase in stability of Smad4 (K113R/K159R) is relatively modest ( [17, 18] ; J. Long and F. Liu, unpublished work). In contrast, the K113R/K159R double mutant has a much higher activity than the wild-type Smad4 in the GAL4 fusion assay, which measures intrinsic transcriptional activity. Based on these and other observations presented above, we conclude that sumoylation inhibits Smad4 transcriptional activity. Thus sumoylation of Smad4 has different roles. Sumoylation of Smad4 regulates its stability and represses Smad4 transcriptional activity. This can translate into distinct effects on different promoters. Sumoylation can also regulate protein subcellular localization [4, 8] . It has been shown that sumoylation of Smad4 increases its nuclear accumulation at basal level and in the presence of TGF-β [18] . It has also been shown that, in the presence of PIASy, Smad4 redistributes from a diffuse nuclear localization to subnuclear speckles that contain SUMO-1 and PIASy [17] . Such redistribution often correlates with inhibition of transcription. For example, PIASy can sequester LEF1 in the nuclear bodies and repress its activity [28] . SUMO-1-modified repressive forms of LEF-1 and Sp3 have been shown to localize to the nuclear periphery and nuclear dots [10, 28] . In contrast, the more transcriptionally active forms, which do not contain SUMO-1, have a more diffuse nuclear localization [10, 28] . Sumoylation, nuclear body localization and transcriptional repression are often closely linked. Therefore the observation that PIASy causes Smad4 redistribution into subnuclear speckles is consistent with our conclusion that sumoylation of Smad4 inhibits its transcriptional activity. Accordingly, expression of SUMO-1, Ubc9 and PIASy together elicited inhibitory effects on several TGF-β-responsive promoters analysed (Figure 2A ; and results not shown). In addition to PIASy, PIAS1, PIASxα and PIASxβ can also enhance Smad4 sumoylation ( [17, 29] ; J. Long and F. Liu, unpublished work).
How does sumoylation inhibit Smad4 transcriptional activity? The Smad activation domain (SAD; amino acids 274-322) in the linker region of Smad4 plays an essential role in Smad4 transcriptional activity [30] . SUMO modification at the major (Lys 159 ) site, which is also located in the linker region of Smad4, may adversely affect the function of the SAD. In addition, SUMO modification of Smad4 may change the conformation, thus inhibiting the assembly of active transcriptional complexes or promoting the assembly of transcriptional repressor complexes, such as transcriptional corepressor complexes that contain HDAC. In this regard, it has been shown that SUMO-dependent repression of p300 can be mediated by recruitment of HDAC6 [13] . SUMO-1 has also been shown to interact with the CHD3/zinc-finger helicase that is present in the HDAC complexes [14] . Interestingly, recent studies have shown that sumoylation of histone H4 leads to transcriptional repression [15] . Conceivably, interaction between Smad4 and Ubc9 not only leads to Smad4 sumoylation, but also recruits Ubc9 to the promoter, which may concomitantly result in the sumoylation of histone H4 and thus transcriptional repression. Although the exact mechanism remains to be elucidated, our finding that sumoylation represses Smad4 transcriptional activity provides new insights into TGF-β-mediated gene regulation.
